Compile Data Set for Download or QSAR
Report error Found 117 Enz. Inhib. hit(s) with all data for entry = 11520
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622513(US20230312583, Compound I-9)
Affinity DataIC50: 0.0250nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622509(US20230312583, Compound I-5)
Affinity DataIC50: 0.0250nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622508(US20230312583, Compound I-4)
Affinity DataIC50: 0.0250nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622511(US20230312583, Compound I-7)
Affinity DataIC50: 0.0250nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 0.0310nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622514(US20230312583, Compound I-10)
Affinity DataIC50: 0.143nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50: 0.175nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622505(US20230312583, Compound I-1)
Affinity DataIC50: 0.210nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622520(US20230312583, Compound II-1)
Affinity DataIC50: 0.214nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622507(US20230312583, Compound I-3)
Affinity DataIC50: 0.455nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622513(US20230312583, Compound I-9)
Affinity DataIC50: 0.880nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 0.984nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 1nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622506(US20230312583, Compound I-2)
Affinity DataIC50: 1.09nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622515(US20230312583, Compound I-11)
Affinity DataIC50: 1.19nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622516(US20230312583, Compound I-12)
Affinity DataIC50: 1.25nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622516(US20230312583, Compound I-12)
Affinity DataIC50: 1.26nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622511(US20230312583, Compound I-7)
Affinity DataIC50: 1.34nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50: 1.44nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50: 1.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 1.55nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50: 1.55nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 1.56nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622515(US20230312583, Compound I-11)
Affinity DataIC50: 1.58nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622505(US20230312583, Compound I-1)
Affinity DataIC50: 1.59nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622509(US20230312583, Compound I-5)
Affinity DataIC50: 1.99nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622508(US20230312583, Compound I-4)
Affinity DataIC50: 2.20nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 2.63nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622520(US20230312583, Compound II-1)
Affinity DataIC50: 2.91nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 2.95nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622517(US20230312583, Compound I-13)
Affinity DataIC50: 3.17nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622506(US20230312583, Compound I-2)
Affinity DataIC50: 3.38nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622517(US20230312583, Compound I-13)
Affinity DataIC50: 3.48nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 3.54nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622514(US20230312583, Compound I-10)
Affinity DataIC50: 3.63nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622507(US20230312583, Compound I-3)
Affinity DataIC50: 3.71nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 6.18nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 8.34nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622510(US20230312583, Compound I-6)
Affinity DataIC50: 11.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 11.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622513(US20230312583, Compound I-9)
Affinity DataIC50: 15nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622516(US20230312583, Compound I-12)
Affinity DataIC50: 15nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622510(US20230312583, Compound I-6)
Affinity DataIC50: 15.4nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622508(US20230312583, Compound I-4)
Affinity DataIC50: 16.6nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622519(US20230312583, Compound I-15)
Affinity DataIC50: 19.3nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50: 21.3nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622513(US20230312583, Compound I-9)
Affinity DataIC50: 22.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 23.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622509(US20230312583, Compound I-5)
Affinity DataIC50: 25.6nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622519(US20230312583, Compound I-15)
Affinity DataIC50: 26.3nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Displayed 1 to 50 (of 117 total ) | Next | Last >>
Jump to: